Global Primary Biliary Cirrhosis Drug Market Size, Share, Trends and Forecast 2019

Description


The global Primary Biliary Cirrhosis Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Primary Biliary Cirrhosis Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Primary Biliary Cirrhosis Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
AlbireoPharma
CymaBay Therapeutics, Inc.
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Intercept Pharmaceuticals, Inc.
Johnson & Johnson
MediGene AG
NGM Biopharmaceuticals, Inc.
Virobay Inc.

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Budesonide
FFP-104
GSK-2330672
MBX-8025
NGM-282
Others

Segment by Application
Clinic
Hospital
Others

TABLE OF CONTENT

Table of Contents

Executive Summary
1 Primary Biliary Cirrhosis Drug Market Overview
1.1 Product Overview and Scope of Primary Biliary Cirrhosis Drug
1.2 Primary Biliary Cirrhosis Drug Segment by Type
1.2.1 Global Primary Biliary Cirrhosis Drug Production Growth Rate Comparison by Type (2014-2025)
1.2.2 Budesonide
1.2.3 FFP-104
1.2.4 GSK-2330672
1.2.5 MBX-8025
1.2.6 NGM-282
1.2.7 Others
1.3 Primary Biliary Cirrhosis Drug Segment by Application
1.3.1 Primary Biliary Cirrhosis Drug Consumption Comparison by Application (2014-2025)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.3 Global Primary Biliary Cirrhosis Drug Market by Region
1.3.1 Global Primary Biliary Cirrhosis Drug Market Size Region
1.3.2 North America Status and Prospect (2014-2025)
1.3.3 Europe Status and Prospect (2014-2025)
1.3.4 China Status and Prospect (2014-2025)
1.3.5 Japan Status and Prospect (2014-2025)
1.3.6 Southeast Asia Status and Prospect (2014-2025)
1.3.7 India Status and Prospect (2014-2025)
1.4 Global Primary Biliary Cirrhosis Drug Market Size
1.4.1 Global Primary Biliary Cirrhosis Drug Revenue (2014-2025)
1.4.2 Global Primary Biliary Cirrhosis Drug Production (2014-2025)

2 Global Primary Biliary Cirrhosis Drug Market Competition by Manufacturers
2.1 Global Primary Biliary Cirrhosis Drug Production Market Share by Manufacturers (2014-2019)
2.2 Global Primary Biliary Cirrhosis Drug Revenue Share by Manufacturers (2014-2019)
2.3 Global Primary Biliary Cirrhosis Drug Average Price by Manufacturers (2014-2019)
2.4 Manufacturers Primary Biliary Cirrhosis Drug Production Sites, Area Served, Product Types
2.5 Primary Biliary Cirrhosis Drug Market Competitive Situation and Trends
2.5.1 Primary Biliary Cirrhosis Drug Market Concentration Rate
2.5.2 Primary Biliary Cirrhosis Drug Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Primary Biliary Cirrhosis Drug Production Market Share by Regions
3.1 Global Primary Biliary Cirrhosis Drug Production Market Share by Regions
3.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Regions (2014-2019)
3.3 Global Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
3.4 North America Primary Biliary Cirrhosis Drug Production
3.4.1 North America Primary Biliary Cirrhosis Drug Production Growth Rate (2014-2019)
3.4.2 North America Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
3.5 Europe Primary Biliary Cirrhosis Drug Production
3.5.1 Europe Primary Biliary Cirrhosis Drug Production Growth Rate (2014-2019)
3.5.2 Europe Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
3.6 China Primary Biliary Cirrhosis Drug Production (2014-2019)
3.6.1 China Primary Biliary Cirrhosis Drug Production Growth Rate (2014-2019)
3.6.2 China Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
3.7 Japan Primary Biliary Cirrhosis Drug Production (2014-2019)
3.7.1 Japan Primary Biliary Cirrhosis Drug Production Growth Rate (2014-2019)
3.7.2 Japan Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Primary Biliary Cirrhosis Drug Consumption by Regions
4.1 Global Primary Biliary Cirrhosis Drug Consumption by Regions
4.2 North America Primary Biliary Cirrhosis Drug Consumption (2014-2019)
4.3 Europe Primary Biliary Cirrhosis Drug Consumption (2014-2019)
4.4 China Primary Biliary Cirrhosis Drug Consumption (2014-2019)
4.5 Japan Primary Biliary Cirrhosis Drug Consumption (2014-2019)

5 Global Primary Biliary Cirrhosis Drug Production, Revenue, Price Trend by Type
5.1 Global Primary Biliary Cirrhosis Drug Production Market Share by Type (2014-2019)
5.2 Global Primary Biliary Cirrhosis Drug Revenue Market Share by Type (2014-2019)
5.3 Global Primary Biliary Cirrhosis Drug Price by Type (2014-2019)
5.4 Global Primary Biliary Cirrhosis Drug Production Growth by Type (2014-2019)

6 Global Primary Biliary Cirrhosis Drug Market Analysis by Applications
6.1 Global Primary Biliary Cirrhosis Drug Consumption Market Share by Application (2014-2019)
6.2 Global Primary Biliary Cirrhosis Drug Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Primary Biliary Cirrhosis Drug Business
7.1 AlbireoPharma
7.1.1 AlbireoPharma Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.1.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.1.4 Main Business and Markets Served
7.2 CymaBay Therapeutics, Inc.
7.2.1 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.2.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.2.4 Main Business and Markets Served
7.3 Dr. Falk Pharma GmbH
7.3.1 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.3.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.3.4 Main Business and Markets Served
7.4 Enanta Pharmaceuticals, Inc.
7.4.1 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.4.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.4.4 Main Business and Markets Served
7.5 GlaxoSmithKline Plc
7.5.1 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.5.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.5.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.5.4 Main Business and Markets Served
7.6 Intercept Pharmaceuticals, Inc.
7.6.1 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.6.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.6.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.6.4 Main Business and Markets Served
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.7.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.7.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.7.4 Main Business and Markets Served
7.8 MediGene AG
7.8.1 MediGene AG Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.8.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.8.3 MediGene AG Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.8.4 Main Business and Markets Served
7.9 NGM Biopharmaceuticals, Inc.
7.9.1 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.9.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.9.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.9.4 Main Business and Markets Served
7.10 Virobay Inc.
7.10.1 Virobay Inc. Primary Biliary Cirrhosis Drug Production Sites and Area Served
7.10.2 Primary Biliary Cirrhosis Drug Product Introduction, Application and Specification
7.10.3 Virobay Inc. Primary Biliary Cirrhosis Drug Production, Revenue, Price and Gross Margin (2014-2019)
7.10.4 Main Business and Markets Served

8 Primary Biliary Cirrhosis Drug Manufacturing Cost Analysis
8.1 Primary Biliary Cirrhosis Drug Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Primary Biliary Cirrhosis Drug
8.4 Primary Biliary Cirrhosis Drug Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.2 Primary Biliary Cirrhosis Drug Distributors List
9.3 Primary Biliary Cirrhosis Drug Customers

10 Market Dynamics
10.1 Market Trends
10.2 Opportunities
10.3 Market Drivers
10.4 Challenges
10.5 Influence Factors

11 Global Primary Biliary Cirrhosis Drug Market Forecast
11.1 Global Primary Biliary Cirrhosis Drug Production, Revenue Forecast
11.1.1 Global Primary Biliary Cirrhosis Drug Production Growth Rate Forecast (2019-2025)
11.1.2 Global Primary Biliary Cirrhosis Drug Revenue and Growth Rate Forecast (2019-2025)
11.1.3 Global Primary Biliary Cirrhosis Drug Price and Trend Forecast (2019-2025)
11.2 Global Primary Biliary Cirrhosis Drug Production Forecast by Regions (2019-2025)
11.2.1 North America Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2019-2025)
11.2.2 Europe Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2019-2025)
11.2.3 China Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2019-2025)
11.2.4 Japan Primary Biliary Cirrhosis Drug Production, Revenue Forecast (2019-2025)
11.3 Global Primary Biliary Cirrhosis Drug Consumption Forecast by Regions (2019-2025)
11.3.1 North America Primary Biliary Cirrhosis Drug Consumption Forecast (2019-2025)
11.3.2 Europe Primary Biliary Cirrhosis Drug Consumption Forecast (2019-2025)
11.3.3 China Primary Biliary Cirrhosis Drug Consumption Forecast (2019-2025)
11.3.4 Japan Primary Biliary Cirrhosis Drug Consumption Forecast (2019-2025)
11.4 Global Primary Biliary Cirrhosis Drug Production, Revenue and Price Forecast by Type (2019-2025)
11.5 Global Primary Biliary Cirrhosis Drug Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

Choose License Type

Checkout Inquiry Sample